EPICENTRX, INC.
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.epicentrx.com
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)β’ Click on a phase to view related trials
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
- Conditions
- Oral Mucositis
- Interventions
- Radiation: Intensity Modulated Radiation Therapy (IMRT)
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT05966194
- Locations
- πΊπΈ
Willis Knighton Cancer Center, Shreveport, Louisiana, United States
πΊπΈUniversity of Michigan, Ann Arbor, Michigan, United States
πΊπΈBanner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
- Conditions
- Carcinoma, Small Cell Lung
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 292
- Registration Number
- NCT05566041
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States
πΊπΈThe University of Kansas Cancer Center, Westwood, Kansas, United States
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
- Conditions
- Solid Tumor, AdultSarcomaSarcoma,Soft TissueChondrosarcomaCancerNeoplasms
- Interventions
- Drug: Checkpoint Inhibitor, Immune
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04673942
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈCalifornia Cancer Associates for Research and Excellence, cCARE, San Marcos, California, United States
πΊπΈProvidence Saint John's Health Center, Santa Monica, California, United States
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
- Conditions
- Brain Tumor, RecurrentBrain Tumor, PediatricCentral Nervous System NeoplasmsUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04525014
- Locations
- πΊπΈ
Texas Children's Cancer Center, Houston, Texas, United States
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
- Conditions
- Carcinoma, Small Cell Lung
- Interventions
- Combination Product: RRx-001 + eLOOP Device
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03699956
- Locations
- πΊπΈ
Centura Health Research Center, Denver, Colorado, United States
πΊπΈMid Florida Hematology and Oncology Center, Orange City, Florida, United States
πΊπΈAdventHealth Hematology and Oncology, Orlando, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- Next